Response to: ‘2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?‘ by Malaviya
Authors:
- 1 November 2018
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (11) , e78
Abstract
We are grateful for the insightful and highly relevant question raised by Dr Malaviya1 concerning the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. The question concerns autoantibodies, and in particular myositis-specific autoantibodies (MSAs), and why only the anti-Jo-1 autoantibody is included in the new classification criteria. We understand the concern that was raised and we have discussed the limitation of having limited data on MSAs in our publication.2 This letter gives us a possibility to expand on this limitation and include some more explanations. Our study was initiated more than 10 years ago, and during the last decade we have seen a great advancement in the knowledge of autoantibodies specific for and associated with idiopathic inflammatory myopathies (IIM). This includes identification of several new MSAs, as well as advancement in methods used to detect MSAs that have made it possible to …Keywords
This publication has 2 references indexed in Scilit:
- 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?Annals of the Rheumatic Diseases, 2018
- 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsAnnals of the Rheumatic Diseases, 2017